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ABSTRACT
Background Merkel cell carcinoma (MCC) is associated 
with high recurrence rates and poor survival when 
metastatic disease is present. The immune checkpoint 
inhibitor avelumab has shown high response rates (RRs) 
and durable responses in patients with advanced MCC 
(aMCC) in clinical trials. To date, only results from clinical 
trials, patients treated in an expanded access program 
and very small numbers of patients have been reported. In 
this study, detailed real- world efficacy and toxicity data of 
avelumab in patients with aMCC are reported.
Methods Patients with aMCC treated in four dedicated 
referral centers in the Netherlands were analyzed from 
February 2017 until December 2019. Patients were 
included if they had received at least one administration of 
avelumab, regardless of previous lines of therapy. Patient 
data were collected retrospectively from patient records. 
Primary endpoints were response rate (RR) and duration of 
response (DOR). Secondary endpoints were progression- 
free survival (PFS), overall survival (OS), and toxicity.
Results Fifty- four patients received avelumab. Eight 
(15%) patients had locally advanced disease (laMCC). In 
40 (74%) patients, avelumab was first- line treatment, 
these included all patients with laMCC. The median 
follow- up was 8.9 (range 0.5–35.9) months. RR was 57% 
(n=31) with 24% (n=13) of patients achieving a complete 
response. The median DOR was 8.4 (range 1.3–22.1) 
months and 23 (43%) patients had an ongoing response 
at the end of the study. The median PFS was 8.6 (95% CI 
1.6–15.5) months, and the median OS was 25.8 (95% CI 
9.1–42.4) months. Six (11%) patients experienced grade 3 
toxicity. No grade 4–5 toxicity was seen.
Conclusions In this real- world cohort, clinical efficacy 
and toxicity outcomes in clinical practice were in line with 
results from clinical trials and showed relatively high RRs 
and durable responses in patients with aMCC.
INTRODUCTION
Merkel cell carcinoma (MCC) is a rare and 
potentially aggressive neuroendocrine carci-
noma of the skin with an incidence of around 
0.5–0.8/100 000.1–4 Incidence has been rising 
over the last few decades.2 3 This is thought 
to be due to not only improved diagnos-
tics and better awareness of this illness, but 
also increasing sun exposure and an aging 
population. The median age of presentation 
is 75 years and in approximately 7%–27% of 
patients regional or distant metastases are 
present at diagnosis.1 2 Prior to the intro-
duction of immunotherapy for this disease, 
patients who no longer had curative, surgical 
treatment options due to metastatic MCC 
(mMCC) or locally advanced MCC (laMCC), 
had 5- year overall survival (OS) rates of only 
7%–12%.5 6 Treatment strategies for advanced 
MCC (aMCC), including both laMCC and 
mMCC, were historically based on those for 
other small cell malignancies, such as small 
cell lung cancer, and mostly consisted of 
polychemotherapy. Although initial response 
rates (RRs) of aMCC to platinum- based 
chemotherapy were high, patients rapidly 
relapsed and no durable responses or survival 
benefit have been reported.1 7
MCC is associated with two different path-
ways of pathogenesis. The first route involves 
the Merkel cell polyomavirus (MCV). MCV 
is present in up to 80% of patients with 
MCC in the Northern hemisphere and 
integrates into the genome of cells driving 
oncogenic processes such as expression of 
T- antigen oncoproteins.8–11 In MCV- negative 
MCC, exposure to ultraviolet (UV) radia-
tion appears important in the pathogenesis. 
MCV- negative tumors mostly arise from sun- 
exposed areas of the skin and show a high 
mutational burden and adaptive immune 
responses that are associated with chronic 
exposure to UV radiation.12 13 These alterna-
tive pathways of pathogenesis both provide a 
good rationale for treatment with immune 
checkpoint inhibitors (ICI).14 15
Several clinical trials showed beneficial 
results of ICI, such as programmed cell 
death-1/programmed cell death ligand-1 
(PD- (L)1) inhibitors, in the treatment of 
aMCC.8 16 17 Pembrolizumab was shown to 
have an objective RR (ORR) of 56%, with 
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progression- free survival (PFS) at 6 months of 67% in 26 
patients with aMCC.17
In 2016, the JAVELIN study, a phase II clinical trial that 
investigated avelumab treatment in patients with aMCC, 
showed significant and durable responses.8 In this study, 
88 patients who had progressed after chemotherapy were 
treated with avelumab and an ORR of 31.8% was seen, 
with 8 patients achieving a complete response (CR) and 
20 patients a partial response (PR). The median follow- up 
was 10.4 months. Based on this study, patients in the Neth-
erlands were able to receive avelumab within an expanded 
access program (EAP). Avelumab was granted accelerated 
approval for aMCC by the Food and Drug Administration 
in North America in March 2017, which was followed by 
the European Medicines Agency in September of 2017. 
In November of 2017, reimbursement in the Netherlands 
followed and avelumab was integrated into the routine 
management of patients with aMCC.18
The population of patients with aMCC is frequently 
elderly and frail, making it essential to determine whether 
the results described in a clinical trial population can be 
replicated in a real- world setting. In 2019, Knepper et al 
performed a large genomic analysis of patients with MCC, 
and investigated the response to various ICI in 36 patients 
with aMCC, of which 10 were treated with avelumab. 
There, a RR of 44% was seen in all 36 patients.13 More 
recently, a large study was performed in an elegant 
attempt to evaluate the clinical efficacy and safety of 
avelumab in the real- world population. There, the authors 
included patients with aMCC who had received avelumab 
in the EAP. They found that ORR was 47%, with 23% of 
patients achieving a CR. Unfortunately, although a large 
number of patients were evaluable for response (n=240, 
46% of total), data were limited because the evaluation of 
progression and toxicity were not documented according 
to a study or clinical protocol, but was at the discretion 
of the treating physician to document in the EAP system. 
Also, the duration of response (DOR) was merely based 
on the resupply of avelumab and data on the medical 
history of patients included were sparse.19
Both the clinical trials and the results from the EAP 
indicate an auspicious effect of avelumab in treatment 
with aMCC, but detailed data on patients with aMCC 
treated with avelumab in routine clinical practice are still 
lacking.
In the Netherlands, patients with aMCC are treated in 
four dedicated tertiary referral centers across the country. 
In this nationwide study, we aimed to evaluate the efficacy 
and toxicity of avelumab in a large real- world cohort of 
patients with aMCC treated in routine clinical practice in 
the Netherlands.
METHODS
Patients
Patients with aMCC treated with avelumab since the intro-
duction of the EAP in the Netherlands were included 
from all four MCC referral centers from February 2017 
until December 2019. Data were collected retrospec-
tively and patients were followed- up until death or end 
of follow- up. Patients were excluded if they had received 
other types of ICI prior to avelumab. Histopathological 
analyses were performed during the diagnostic workup 
according to the standard of care for these tumors. MCV 
positivity was determined immunohistochemically using a 
CM2B4 monoclonal antibody as described previously.20 21
Avelumab was administered in a 2 weekly interval as per 
institutional protocol. Premedication consisting of 2 mg 
clemastine and 1000 mg paracetamol was administered 
intravenously during the first three cycles and continued 
thereafter only if infusion reactions occurred.
Patient characteristics, response to avelumab, adverse 
effects, and toxicity were gathered from electronic patient 
records. All patients gave consent to use their medical 
data according to institutional protocols.
Outcomes
Primary endpoints were RR and DOR. Response evalua-
tion by CT or positron emission tomography (PET- )CT 
was performed at approximately 12- week intervals. As 
this study was not conducted within a trial setting, the 
response was reported in radiological records according 
to routine diagnostic practice. When the radiological 
evaluation was not possible, clinical parameters such as 
changes in visible skin lesions that were measured with 
a caliper or other evaluable parameters such as perfor-
mance status were used. For biochemical response 
measurements, all centers used lactate dehydrogenase 
(LDH) with an upper limit of normal (ULN) 248 U/L, 
and additionally, neuron- specific enolase (NSE) with a 
ULN 18.2 μg/L was used in the largest referral center.22 
Responses were extracted retrospectively from patient 
records and radiology reports. The measurements in the 
reports initially described by a radiologist were reassessed 
according to RECIST criteria. PR was defined as radio-
graphic shrinkage of tumors ≥30%. In the absence of 
radiological response evaluation, visible and/or palpable 
shrinkage ≥30% of skin tumors and/or lymph nodes were 
evaluated. CR was defined as a complete metabolic and 
radiological response on PET- CT. When mixed response 
(MR) was present at ≥2 consecutive response evalua-
tions, defined as ≥30% tumor shrinkage, with simulta-
neous growth ≥20% of other lesions and/or occurrence 
of new lesions, a consensus on continuation or cessation 
of avelumab was reached in a multidisciplinary team 
(MDT). The decision to perform salvage treatment 
including surgery or radiotherapy was also reached in 
an MDT. Progressive disease (PD) was defined as radio-
graphic tumor growth ≥20% and/or growth of visible skin 
tumors, and/or increase of biochemical markers such as 
LDH and/or NSE above the ULN, and/or deterioration 
of a patients’ performance status due to aMCC. DOR was 
defined as the time from first documented PR or CR until 
documented PD, death, or end of follow- up.
Secondary endpoints were PFS, OS and toxicity. PFS and 
OS were defined as the time from the first administration 
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of avelumab until documented progression or death, 
respectively. Patients were censored at the end of the 
study. Toxicity was evaluated according to CTCAE V.5.0, 
grades 1–5 were included.
Statistical analysis
Descriptive statistics with median and ranges were used 
for continuous variables and frequency and percentages 
for categorical variables. Pearson’s χ2 test was used to 
compare responses between groups and for the forest 
plot, univariable Clopper- Pearson calculations were 
performed to establish confidence intervals for propor-
tions of patients that responded to avelumab. The Kaplan- 
Meier method was used to evaluate OS and PFS and the 
log- rank test was performed for comparison between first- 
line and second- line treatment. IBM SPSS V.25 was used 
to perform all statistical analyses.
RESULTS
Baseline characteristics
We identified 55 patients with aMCC who had received at 
least one dose of avelumab, 54 of these patients fulfilled 
the inclusion criteria. One patient was excluded due 
to prior treatment with ICI (nivolumab). Two patients 
received avelumab in the EAP. The first administration 
of avelumab was in February 2017, the last patient started 
treatment in September 2019.
Patients were first diagnosed with MCC at a median 
age of 71 (range 50–86) and had a median age of 73 
(range 53–88) years at the start of avelumab. Thirty- four 
(63%) patients were male individuals. Primary tumor 
localizations were head and neck, trunk, extremities, 
or unknown primary tumor (UPMCC) in 13 (24%), 8 
(15%), 25 (46%), and 8 (15%) patients, respectively. 
Eight (15%) patients had locally advanced (stage IIIB/
laMCC) disease and 46 (85%) had the distant disease 
(stage IV/mMCC) at the start of avelumab administra-
tion. Of the latter, 35 (65%) patients had distant nodal 
and/or (sub)cutaneous disease, and in 19 (30%), visceral 
and/or peritoneal/mesenterial metastasis were present. 
In 12 (22%) patients, one organ site was involved, and 
in 4 (7%) patients, disease was present in two organs. 
Seven (13%) patients had a history of immunosuppres-
sion, including chronic lymphatic leukemia, Walden-
ström’s macroglobulinemia, human deficiency virus, 
idiopathic pulmonary fibrosis, and a kidney transplant. 
MCV status was determined in 21 patients. Of these, 15 
(71%) was positive. PD- (L)1 expression was not deter-
mined in routine clinical practice, hence no data on 
PD- (L)1 expression were available. LDH levels were avail-
able for 50 patients at the start of avelumab. Of these, 
29 (58%) had elevated LDH levels above ULN. Baseline 
characteristics are shown in table 1. Avelumab was first- 
line treatment for all patients with laMCC (n=8, 15%) 
and in 32 (59%) patients with mMCC; the remaining 14 
(26%) patients with mMCC received avelumab as second- 
line treatment. Prior therapy in all patients consisted of 
Table 1 Baseline characteristics for all included patients
Characteristics All patients (N=54)
Sex, n (%)
  Male 34 (63)
  Female 20 (37)
Immunosuppression history, n (%)
  CLL 3 (6)
  WM 1 (2)
  HIV 1 (2)
  IPF 1 (2)
  KT recipient 1 (2)
Age (years), median (range)
  At diagnosis 71.1 (50.2–86.3)
  At start IT 73.0 (53.0–88.0)
Primary tumor site, n (%)
  Head and neck 13 (24)
  Trunk 8 (15)
  Extremity 25 (46)
  Unknown primary 8 (15)
WHO performance status, n (%)
  0 17 (32)
  1 32 (59)
  2 5 (9)
Disease status, n (%)
  Locally advanced 8 (15)
  Distant disease 46 (85)
Metastasis, n (%)
  Visceral metastases* 19 (35)
  Nodal or (sub)cutaneous metastases 35 (65)
No. of organ sites involved,† n (%)
  1 12 (22)
  2 4 (8)
Line of therapy, n (%)
  First 40 (74)
  Second 14 (26)
Radiotherapy
  Yes 31 (57)
  No 23 (43)
MCV, n (%)
  Yes 15/21 (71)
  No 6/21 (29)
LDH, n (%)
  Yes 21/50 (39)
  No 29/50 (54)
  Missing 4/50 (7)
*Also including distant mesenterial or peritoneal metastasis.
†Organ sites included liver, bone, adrenal cortex, pancreas, intestine, 
pleura.
CLL, chronic lymphatic leukemia; IPF, idiopathic pulmonary 
fibrosis; IT, immunotherapy; KT, kidney transplant; LDH, lactate 
dehydrogenase; MCV, Merkel cell polyomavirus; WM, Waldenström’s 
macroglobulinemia.
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platinum- based chemotherapy. Additionally, 31 (57%) 
patients had received radiotherapy on either primary 
tumor area or metastasis prior to avelumab initiation. All 
patients had a performance score (PS) ≤2. Patients with a 
performance score of 2 (n=5, 9%) were all in the mMCC 
group. In patients with laMCC, 3 (38%) had PS 0 and 5 
(63%) had PS 1, compared with 14 (30%) and 27 (58%) 
patients with mMCC, respectively. Patients received a 
median of 10 (range 1–39) doses of avelumab and the 
median follow- up time was 8.9 (range 0.5–35.9) months.
Response to avelumab
Three patients (6%) were not evaluable for response: two 
died due to comorbidities before response evaluation. 
Comorbidities included rapidly progressive dementia and 
a superinfection due to pre- existent idiopathic pulmo-
nary fibrosis shortly after avelumab administration. One 
patient discontinued avelumab after one infusion due to 
an allergic reaction and was referred to the general prac-
titioner for palliative care.
Out of all 54 patients, objective response to avelumab 
was seen in 57% (n=31). In 24% (n=13) of patients, best 
overall response (BOR) was a CR, PR was seen in 33% 
(n=18), stable disease in 6% (n=3), MR in 4% (n=2), and 
PD in 28% (n=15) of patients. BORs are shown in figure 1. 
Response to avelumab therapy in all patients divided and 
analyzed by subgroups are shown in figure 2. In patients 
with laMCC, RR was 50% (n=4), compared with 59% 
(n=27) in patients with mMCC (p=0.646). Regarding CRs: 
in patients with laMCC 25% (n=2) achieved a CR, and in 
patients with mMCC, 24% (n=11) patients achieved a CR 
(p=0.947). In five (9%) patients, salvage surgery or radio-
therapy was performed for either residual tumor lesions 
(n=3) or new solitary lesions (n=2). All salvage interven-
tions were in patients with mMCC. RR was 41% (n=7), 
63% (n=20), and 80% (n=4) in patients with PS 0, 1, 
and 2, respectively (p=0.200). Of these, CR was achieved 
in 12% (n=2), 28% (n=9), and 40% (n=2), respectively 
(p=0.303).
In patients with UPMCC, 63% (n=5) had an objec-
tive response, whereas in patients with known primary 
locations 56% (n=26) had a response (p=0.752). CRs 
occurred in 25% (n=2) of patients with UPMCC, and 
in 24% (n=11) of patients with known primary tumors 
(p=0.947).
Out of the 19 patients with visceral metastases 
(including peritoneal or mesenteric metastases), 63% 
(n=12) had a response compared with 54% (n=19) out 
of the remaining 35 patients who had nodal or subcuta-
neous metastases only (p=0.529). CRs were achieved in 
37% (n=7) of patients with visceral metastases and in 17% 
(n=6) of patients without visceral metastases (p=0.106).
In the 50 patients for whom LDH levels were known, 
no differences in response to avelumab between elevated 
LDH levels and normal LDH levels were seen. In patients 
with elevated LDH levels, response was seen in 62% 
(n=13) of patients compared with 55% (n=16) of patients 
who had normal LDH levels (p=0.634). Interestingly, 
in patients who had received avelumab as second- line 
treatment, 11 of 14 (79%) had a response compared 
with patients who received avelumab as first- line treat-
ment, of which 20 of 40 (50%) patients had a response 
(0.063). In contrast, CRs were present in 28% (n=11) of 
patients receiving the first- line avelumab, compared with 
14% (n=2) of patients treated with second- line avelumab 
(p=0.302). We saw no difference in response to avelumab 
for patients who had received radiotherapy prior to 
avelumab initiation: of the 31 patients who underwent 
radiotherapy, 52% (n=16) had a response compared with 
65% (n=15) out of 23 patients who did not (p=0.317).
In patients with a history of immunosuppression, 29% 
(n=2) had a PR, and no CRs occurred in this group.
Figure 1 Best overall response during follow- up for all 54 
patients. CR, complete response; MR, mixed response; NE, 
not evaluable; PR, partial response; PD, progressive disease; 
SD, stable disease.
Figure 2 Response rates by subgroups. *Response rates 
calculated for patient with known viral status. **Response 
rates calculated for patient with known LDH levels at the 
start of avelumab. LDH, lactate dehydrogenase; MCV, Merkel 
cell polyomavirus; WHO PS, World Health Organization 
performance status.
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The median DOR was 8.4 (range 1.3–22.1) months, and 
median PFS was 8.6 (95% CI 1.6–15.5) months. The esti-
mated median OS was 25.8 (95% CI 9.1–42.4) months. 
We saw no significant differences in PFS and OS between 
patients treated with avelumab in first- line or second- line 
setting, p=0.337 and p=0.548, respectively. PFS and OS 
are shown in figure 3A,B. Responses were ongoing in 23 
(43%) patients at the end of follow- up. PD occurred in 7 
of 19 patients for whom BOR was PR. All seven patients 
were on active therapy at the time of progression. For 
patients who achieved CR: at the end of the study, 12 of 
13 patients remained free of disease, with a median DOR 
of 12.8 (range 3.6–22.1) months. The remaining patient 
had achieved a CR after 2.6 months and had discontinued 
avelumab treatment after 19 cycles (8.8 months). Recur-
rence occurred 17.2 months after the start of therapy. 
During follow- up, no rechallenges with avelumab were 
initiated for patients who had initially responded but then 
progressed. Clinical activity of avelumab in all patients 
evaluable for response are shown in figure 4.
Out of all 54 patients, 6 (11%) experienced grade 1 
toxicity, which was mostly fatigue. Four (7%) patients 
experienced grade 2 toxicity, which constituted of allergic 
reactions requiring oral intervention, hypothyroidism, 
and hepatitis. Grade 3 toxicity including allergic reactions 
and renal insufficiency resulting in clinical admission 
were seen in five (9%) patients. No grade 4 or 5 toxicities 
were seen. Toxicities are shown in table 2.
DISCUSSION
In this real- world cohort of patients with aMCC, avelumab 
treatment resulted in high RRs, durable responses, and 
manageable toxicities. This study describes a detailed and 
relatively large cohort of patients with patients with aMCC 
outside the setting of a clinical trial or an EAP, showing a 
true representation of the real- world clinical practice for 
patients with aMCC. We demonstrate that avelumab now 
has a prominent role in both first- line and second- line 
treatment for aMCC.
In the 40 patients in our study who received avelumab 
in the first- line setting, we found a RR of 50% with 28% 
achieving a CR. The EAP study found similar results in 
15 patients who were treated with the first- line avelumab, 
where 47% of patients had a response.19 This is also in 
concordance with results seen in clinical trials involving 
Figure 3 (A) Progression free survival all patients, divided by subgroups of patients receiving avelumab in first- line and 
second- line treatment. Median with CI for subgroups. Subgroup comparison with p value by the log- rank test. (B) Overall 
survival of all patients, divided by subgroups of patients receiving avelumab in first- line and second- line treatment. Median with 
CI for subgroups. Subgroups comparison with p value by the log- rank test. NE, not estimable.
Figure 4 Clinical activity of avelumab in all evaluable 
patients (n=51). CR, complete response; PD, progressive 
disease; PR, partial response.
Table 2 Avelumab- associated toxicities
Toxicities Patients, n (%)
Grade 1
  Fatigue 5 (9)
  Hypothyroidism 1 (2)
Grade 2
  Hepatitis 1 (2)
  Allergic/infusion reaction 1 (2)
  Hypothyroidism 2 (4)
Grade 3
  Allergic 3 (6)
  Nausea/vomiting 1 (2)
  Renal insufficiency 1 (2)
Grade 4 0 (0)
Grade 5 0 (0)
Total 15 (28)
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pembrolizumab or avelumab as first- line treatment for 
aMCC.17 23 24
Regarding previous lines of therapy, in the cohort of 36 
patients treated with various ICIs that were investigated by 
Knepper et al, a dramatic decrease in response was seen 
in patients treated with higher therapy lines. There, a RR 
of 75% was found for patient treated with ICI as first- line 
therapy, 39% as second- line therapy, and 18% in third- line 
or higher- line therapy.13 Similarly, in our cohort, patients 
treated with first- line avelumab also had a more favorable 
outcome. We found that nearly all CRs arose in patients 
treated with the first- line avelumab, and responses were 
similar in both laMCC and mMCC, indicating that tumors 
in patients without prior lines of chemotherapy might be 
more sensitive to PD- (L)1 blockade. This supports the 
clinical practice that we see evolving in the Netherlands 
in which avelumab is increasingly being used as first- line 
therapy for mMCC.
Although only 14 patients in our cohort were treated 
with avelumab as second- line therapy for aMCC, still inter-
esting results were seen. When comparing our patients 
receiving avelumab as a second- line treatment for aMCC 
with those from clinical trials, we saw similar rates of CRs: 
14% in our cohort compared with 9% in the JAVELIN 
trial.8 In contrast, the overall ORRs were quite different, 
with 79% in our second- line patients compared with 32% 
in the trial. There, over half of the patients were treated 
with more than one prior line of chemotherapy, and the 
authors suggest that this could have led to more immuno-
logically depleted patients, resulting in worse RRs. This is 
substantiated by the updated results of the JAVELIN trial 
after a median follow- up of 41 months, where a trend 
towards a higher ORR in patients with fewer prior lines 
of therapy was seen.24 This could explain the higher RR 
in our cohort as we had no patients with more than one 
prior line of therapy.
In earlier years, when polychemotherapy was the treat-
ment of choice for aMCC, a more advanced disease stage 
was associated with a worse prognosis. Several epidemio-
logical studies have found that a more advanced disease 
stage is an independent predictor for survival.1 25–30 Inter-
estingly, in studies where patients with aMCC were treated 
with ICI, no significant difference in response to treat-
ment were seen between stage IIIb or IV disease, but a 
trend towards lower RRs remained.8 17 In our cohort, 35% 
of patients had visceral metastases at treatment initiation. 
This is a smaller percentage than was shown in the clinical 
trials, were visceral metastases have been reported to be 
present in 53%–67% of patients.8 16 However, older studies 
that focused on chemotherapy for aMCC, found similar 
or even lower percentages of visceral metastases than in 
our cohort, suggesting that the percentage of visceral 
metastases varies greatly between different study popu-
lations.7 31 Besides this, although we saw no statistically 
different responses, we saw a trend towards higher RRs in 
patients with visceral metastases. This seems contradictory 
to the results from clinical trials.8 32 Finding these differ-
ences may be attributable to the small number of patients 
with visceral metastases (n=19). Another explanation 
might be that because of the retrospective nature of this 
study, we did not perform other measurements of disease 
burden, such as sum of lesion diameter parameters. This 
might underestimate the disease burden in patients with 
nodal and/or subcutaneous disease only, subsequently 
overestimating disease burden in patients with visceral 
metastases. Nevertheless, our cohort represents an accu-
rate representation of radiological documentation and 
response to avelumab in patients with aMCC in routine 
clinical practices. Therefore, these results remain gener-
alizable to clinical practices elsewhere.
Patients with UPMCC have been shown to have a longer 
OS and a higher tumor mutational load than patients 
with known primary tumor locations.33 34 It has, therefore, 
been implied that patients with UPMCC are more likely 
to respond to immunotherapy.33 However, both clinical 
trials involving ICI and this real- world cohort did not 
show different RRs in patients with a UPMCC.8 Potential 
differences may have been missed due to the fact that we 
had only eight (15%) patients with UPMCC.8 Yet our find-
ings are in concordance with results shown in a Dutch 
cohort of 351 patients, where UPMCC was not associated 
with a survival benefit in multivariable analysis.35
As we did not perform additional genomic sequencing, 
data on mutational burden were not available. To deter-
mine whether the mutational burden indeed plays a role 
in the response, larger studies are needed. Recently, 
several potential strategies to involve and study larger 
numbers of patients with aMCC have been described.36 
Future studies should aim to elucidate which patients 
would benefit from ICI by investigating which possible 
biomarkers or genomic characteristics of the tumor are 
associated with response to PD- (L)1 blockade.
CONCLUSION
In the Netherlands, avelumab is increasingly being used 
as first- line and second- line systemic treatment for aMCC. 
In this real- world cohort, RRs, DOR, PFS, and toxicity 
results are promising and essentially in line with results 
found in clinical trials. Although higher RRs were seen in 
patients treated in the second line, more complete and 
durable responses were seen in patients who received 
avelumab as first- line treatment.
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